Unusual case of B cell lymphoma after immunosuppressive treatment for psoriasis

Research output: Contribution to journalArticle

Abstract

Lymphomas may be induced by the systemic immunosuppressive therapies used to treat psoriasis, such as ciclosporin, methotrexate and tumour necrosis factor (TNF)-α blockers. The biologic agents currently used in psoriasis include alefacept, efalizumab, and the TNF-α antagonists etanercept, infliximab, and adalimumab. Infections and cancer are the main possible consequences of intended or unexpected immunosuppression. We report a 59-year-old man with a history of severe psoriasis vulgaris treated with traditional immunosuppressant drugs followed by anti-TNF-α therapy; the patient was firstly hospitalized for an acute cholestatic toxic hepatitis, which we supposed to be related to adalimumab. The first liver biopsy showed active disease with severe hepatocellular damage caused by heavy lymphocytes infiltrate in portal tracts at in the interface with a not conclusive diagnosis of lymphoproliferative disease. The correct diagnosis of T cell/histiocyte-rich large B cell lymphoma (T/HRBCL) was only reached through a gastric biopsy and a second liver biopsy. T/HRBCL is an uncommon morphologic variant of diffuse large B-cell lymphoma not described until now in psoriatic patients receiving immunosuppressive biologic agents. In psoriatic patients, treated with biologic immunosuppressive agents, the suspect of abdominal lymphoma should always be included as differential diagnosis. Abdominal ultrasound evaluation need therefore to be included in the pretreatment screening as in the follow-up surveillance.

Original languageEnglish
Pages (from-to)814-818
Number of pages5
JournalWorld Journal of Hepatology
Volume7
Issue number5
DOIs
Publication statusPublished - 2015

Fingerprint

B-Cell Lymphoma
Immunosuppressive Agents
Psoriasis
Biological Factors
Histiocytes
Tumor Necrosis Factor-alpha
Biopsy
Lymphoma
T-Lymphocytes
Chemical and Drug Induced Liver Injury
Lymphoma, Large B-Cell, Diffuse
Liver
Therapeutics
Methotrexate
Immunosuppression
Cyclosporine
Stomach
Differential Diagnosis
Lymphocytes
Infection

Keywords

  • Diffuse large B-cell lymphoma
  • Immunosuppressant
  • Lymphoma
  • Psoriasis
  • Tumor necrosis factor-α blocker

ASJC Scopus subject areas

  • Hepatology

Cite this

Unusual case of B cell lymphoma after immunosuppressive treatment for psoriasis. / Nosotti, Lorenzo; Baiocchini, Andrea; Bonifati, Claudio; Visco-Comandini, Ubaldo; Mirisola, Concetta; Nonno, Franca Del.

In: World Journal of Hepatology, Vol. 7, No. 5, 2015, p. 814-818.

Research output: Contribution to journalArticle

@article{817535cf481b46bda7ca4bb4b8927920,
title = "Unusual case of B cell lymphoma after immunosuppressive treatment for psoriasis",
abstract = "Lymphomas may be induced by the systemic immunosuppressive therapies used to treat psoriasis, such as ciclosporin, methotrexate and tumour necrosis factor (TNF)-α blockers. The biologic agents currently used in psoriasis include alefacept, efalizumab, and the TNF-α antagonists etanercept, infliximab, and adalimumab. Infections and cancer are the main possible consequences of intended or unexpected immunosuppression. We report a 59-year-old man with a history of severe psoriasis vulgaris treated with traditional immunosuppressant drugs followed by anti-TNF-α therapy; the patient was firstly hospitalized for an acute cholestatic toxic hepatitis, which we supposed to be related to adalimumab. The first liver biopsy showed active disease with severe hepatocellular damage caused by heavy lymphocytes infiltrate in portal tracts at in the interface with a not conclusive diagnosis of lymphoproliferative disease. The correct diagnosis of T cell/histiocyte-rich large B cell lymphoma (T/HRBCL) was only reached through a gastric biopsy and a second liver biopsy. T/HRBCL is an uncommon morphologic variant of diffuse large B-cell lymphoma not described until now in psoriatic patients receiving immunosuppressive biologic agents. In psoriatic patients, treated with biologic immunosuppressive agents, the suspect of abdominal lymphoma should always be included as differential diagnosis. Abdominal ultrasound evaluation need therefore to be included in the pretreatment screening as in the follow-up surveillance.",
keywords = "Diffuse large B-cell lymphoma, Immunosuppressant, Lymphoma, Psoriasis, Tumor necrosis factor-α blocker",
author = "Lorenzo Nosotti and Andrea Baiocchini and Claudio Bonifati and Ubaldo Visco-Comandini and Concetta Mirisola and Nonno, {Franca Del}",
year = "2015",
doi = "10.4254/wjh.v7.i5.814",
language = "English",
volume = "7",
pages = "814--818",
journal = "World Journal of Hepatology",
issn = "1948-5182",
publisher = "Baishideng Publishing Group Co",
number = "5",

}

TY - JOUR

T1 - Unusual case of B cell lymphoma after immunosuppressive treatment for psoriasis

AU - Nosotti, Lorenzo

AU - Baiocchini, Andrea

AU - Bonifati, Claudio

AU - Visco-Comandini, Ubaldo

AU - Mirisola, Concetta

AU - Nonno, Franca Del

PY - 2015

Y1 - 2015

N2 - Lymphomas may be induced by the systemic immunosuppressive therapies used to treat psoriasis, such as ciclosporin, methotrexate and tumour necrosis factor (TNF)-α blockers. The biologic agents currently used in psoriasis include alefacept, efalizumab, and the TNF-α antagonists etanercept, infliximab, and adalimumab. Infections and cancer are the main possible consequences of intended or unexpected immunosuppression. We report a 59-year-old man with a history of severe psoriasis vulgaris treated with traditional immunosuppressant drugs followed by anti-TNF-α therapy; the patient was firstly hospitalized for an acute cholestatic toxic hepatitis, which we supposed to be related to adalimumab. The first liver biopsy showed active disease with severe hepatocellular damage caused by heavy lymphocytes infiltrate in portal tracts at in the interface with a not conclusive diagnosis of lymphoproliferative disease. The correct diagnosis of T cell/histiocyte-rich large B cell lymphoma (T/HRBCL) was only reached through a gastric biopsy and a second liver biopsy. T/HRBCL is an uncommon morphologic variant of diffuse large B-cell lymphoma not described until now in psoriatic patients receiving immunosuppressive biologic agents. In psoriatic patients, treated with biologic immunosuppressive agents, the suspect of abdominal lymphoma should always be included as differential diagnosis. Abdominal ultrasound evaluation need therefore to be included in the pretreatment screening as in the follow-up surveillance.

AB - Lymphomas may be induced by the systemic immunosuppressive therapies used to treat psoriasis, such as ciclosporin, methotrexate and tumour necrosis factor (TNF)-α blockers. The biologic agents currently used in psoriasis include alefacept, efalizumab, and the TNF-α antagonists etanercept, infliximab, and adalimumab. Infections and cancer are the main possible consequences of intended or unexpected immunosuppression. We report a 59-year-old man with a history of severe psoriasis vulgaris treated with traditional immunosuppressant drugs followed by anti-TNF-α therapy; the patient was firstly hospitalized for an acute cholestatic toxic hepatitis, which we supposed to be related to adalimumab. The first liver biopsy showed active disease with severe hepatocellular damage caused by heavy lymphocytes infiltrate in portal tracts at in the interface with a not conclusive diagnosis of lymphoproliferative disease. The correct diagnosis of T cell/histiocyte-rich large B cell lymphoma (T/HRBCL) was only reached through a gastric biopsy and a second liver biopsy. T/HRBCL is an uncommon morphologic variant of diffuse large B-cell lymphoma not described until now in psoriatic patients receiving immunosuppressive biologic agents. In psoriatic patients, treated with biologic immunosuppressive agents, the suspect of abdominal lymphoma should always be included as differential diagnosis. Abdominal ultrasound evaluation need therefore to be included in the pretreatment screening as in the follow-up surveillance.

KW - Diffuse large B-cell lymphoma

KW - Immunosuppressant

KW - Lymphoma

KW - Psoriasis

KW - Tumor necrosis factor-α blocker

UR - http://www.scopus.com/inward/record.url?scp=84928995576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928995576&partnerID=8YFLogxK

U2 - 10.4254/wjh.v7.i5.814

DO - 10.4254/wjh.v7.i5.814

M3 - Article

AN - SCOPUS:84928995576

VL - 7

SP - 814

EP - 818

JO - World Journal of Hepatology

JF - World Journal of Hepatology

SN - 1948-5182

IS - 5

ER -